Adcetris Interactions
There are 654 drugs known to interact with Adcetris (brentuximab), along with 8 disease interactions, and 2 alcohol/food interactions. Of the total drug interactions, 67 are major, and 587 are moderate.
- View all 654 medications that may interact with Adcetris
- View Adcetris alcohol/food interactions (2)
- View Adcetris disease interactions (8)
Most frequently checked interactions
View interaction reports for Adcetris (brentuximab) and the medicines listed below.
- Adcirca (tadalafil)
- Adriamycin (doxorubicin)
- bleomycin
- Blincyto (blinatumomab)
- Braftovi (encorafenib)
- Celebrex (celecoxib)
- CellCept (mycophenolate mofetil)
- Corlanor (ivabradine)
- Cosentyx (secukinumab)
- Cymbalta (duloxetine)
- Cytoxan (cyclophosphamide)
- Emgality (galcanezumab)
- Empliciti (elotuzumab)
- enalapril
- Entyvio (vedolizumab)
- Esbriet (pirfenidone)
- Hemlibra (emicizumab)
- Idhifa (enasidenib)
- Imbruvica (ibrutinib)
- Kalydeco (ivacaftor)
- Kynamro (mipomersen)
- Letairis (ambrisentan)
- Ocrevus (ocrelizumab)
- Ofev (nintedanib)
- Oncovin (vincristine)
- prednisone
- Ravicti (glycerol phenylbutyrate)
- Repatha (evolocumab)
- Stribild (cobicistat / elvitegravir / emtricitabine / tenofovir disoproxil)
- Tecfidera (dimethyl fumarate)
Adcetris alcohol/food interactions
There are 2 alcohol/food interactions with Adcetris (brentuximab).
Adcetris disease interactions
There are 8 disease interactions with Adcetris (brentuximab) which include:
- infections
- tumor lysis syndrome
- hepatotoxicity
- hyperglycemia
- peripheral neuropathy
- pulmonary toxicity
- renal impairment
- Brentuximab vedotin -GI events
Report options
More about Adcetris (brentuximab)
- Adcetris consumer information
- Compare alternatives
- Pricing & coupons
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: CD30 monoclonal antibodies
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Opdivo
Opdivo is used to treat many cancers, such as melanoma, non-small cell lung cancer, malignant ...
Adriamycin
Adriamycin is used for acute lymphoblastic leukemia, acute myeloblastic leukemia, bladder cancer ...
Keytruda
Keytruda is used to treat melanoma, non-small cell lung cancer, malignant pleural mesothelioma ...
Cytoxan
Cytoxan is used for acute lymphocytic leukemia, acute nonlymphocytic leukemia, breast cancer ...
Dacarbazine
Dacarbazine is used for hodgkin's lymphoma, melanoma, melanoma, metastatic
Etoposide
Etoposide is used for cancer, hodgkin's lymphoma, multiple myeloma, ovarian cancer, small cell lung ...
Vincristine
Vincristine is used for acute lymphocytic leukemia, acute myeloid leukemia, anaplastic ...
Nivolumab
Nivolumab is used to treat melanoma, non-small cell lung cancer, malignant pleural mesothelioma ...
Doxorubicin
Doxorubicin is used for acute lymphoblastic leukemia, acute myeloblastic leukemia, bladder cancer ...
Cyclophosphamide
Cyclophosphamide is used for acute lymphocytic leukemia, acute nonlymphocytic leukemia, brain ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.